Annals of Neurology · 2019 · 65 citations · 13 references
Life SciencesNeurologyNeuroscienceImmunopathologyMonoclonal AntibodiesNeuroimmunologyAntibody CharacterizationAntibody StructureNeurodegenerative DiseasesNeurodegenerative DisordersRecombinant AntibodiesTumor AntigensAntibodiesAntibody-mediated Neurologic DiseaseCerebrospinal Fluid Antibody TestingHybridoma Cell LinesParaneoplastic Neurologic SyndromesTransgenic Cell Lines
The pathogenesis of Yo-mediated paraneoplastic cerebellar degeneration (PCD) is unclear. We applied cerebrospinal fluid and serum from PCD patients as well as CDR2 and CDR2L antibodies to neuronal tissue, cancer cell lines, and cells transfected with recombinant CDR2 and CDR2L to elucidate which is the major antigen of Yo antibodies. We found that Yo antibodies bound endogenous CDR2L, but not endogenous CDR2. However, Yo antibodies can bind the recombinant CDR2 protein used in routine clinical testing for these antibodies. Because Yo antibodies only bind endogenous CDR2L, we conclude that CDR2L is the major antigen of Yo antibodies in PCD. ANN NEUROL 2019;86:316-321.
13
Tumor-specific killer cells in paraneoplastic cerebellar degeneration
Matthew L. Albert, Jennifer C. Darnell, Armin Bender et al. · Nature Medicine · 1998 · 449 citations